reverse transcriptase inhibitor

(redirected from Reverse transcriptase inhibitors)
Also found in: Thesaurus, Medical.
Related to Reverse transcriptase inhibitors: Protease inhibitors

reverse transcriptase inhibitor

n. Abbr. RTI
Any of various antiviral compounds that interfere with the activity of the enzyme reverse transcriptase, which is found especially in retroviruses such as HIV. These compounds are divided into two classes: those that are nucleoside analogs (nucleoside reverse transcriptase inhibitors) and those that are not nucleoside analogs (non-nucleoside reverse transcriptase inhibitors).
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.reverse transcriptase inhibitor - an antiviral drug that inhibits the action of reverse transcriptase in retroviruses such as HIV
antiviral, antiviral agent, antiviral drug - any drug that destroys viruses
NNRTI, non-nucleoside reverse transcriptase inhibitor - an antiviral drug used against HIV; binds directly to reverse transcriptase and prevents RNA conversion to DNA; often used in combination with other drugs
NRTI, nucleoside reverse transcriptase inhibitor - an antiviral drug used against HIV; is incorporated into the DNA of the virus and stops the building process; results in incomplete DNA that cannot create a new virus; often used in combination with other drugs
References in periodicals archive ?
Biktarvy is a three-drug combination of bictegravir, a human immunodeficiency virus type 1 integrase strand transfer inhibitor, and emtricitabine and tenofovir alafenamide, both HIV-1 nucleoside analog reverse transcriptase inhibitors, and was approved by the FDA as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy, according to a post to the agency's website.
the subject of the order in the scope of lot 1 is the supply at the cost and risk of the medical device contractor for the genotypic determination of hiv resistance to anti-retroviral drugs - reverse transcriptase inhibitors and protease inhibitors, to laboratories performing research for health policy implementers treating hiv / aids patients, working on the basis of hospitals / medical facilities who have concluded agreements with the national center for aids for the implementation of the health policy of the minister of health, entitled "antiretroviral treatment of people living with hiv in poland for 2017-2021".
Rifampicin, a key component of TB treatment, is a potent inducer of drug metabolism and decreases plasma concentrations of many co-administered drugs, including non-nucleoside reverse transcriptase inhibitors, protease inhibitors and integrase inhibitors.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients The SMART/INSIGHT and DAD Study Groups AIDS, 2008, 22, F17-F24
The group conducted a study, published recently in the New England Journal of Medicine, that investigated the association of cumulative exposure to protease inhibitors and non-nucleoside reverse transcriptase inhibitors with the risk of myocardial infarction.
The survey, which looked at specimens from 3,130 newly diagnosed, drug-naive individuals, found that 4% of infections had mutations conferring resistance to nucleoside reverse transcriptase inhibitors, 7% to nonnucleoside reverse transcriptase inhibitors, and 2% to protease inhibitors.
nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), RNA polymerase inhibitors, integrase inhibitors.
Nucleoside analog reverse transcriptase inhibitors (NRTIs), the first antiretroviral agents to be introduced to the market back in 1987, remain a mainstay of anti-HIV therapy.
But everything changed in the mid 1990s with the advent of two new classes of anti-HIV drugs--first in December 1995 with protease inhibitors, then in June 1996 with nonnucleoside reverse transcriptase inhibitors.
Reverset was also shown to be effective in patients with virus resistant to other commonly used nucleoside analog reverse transcriptase inhibitors (NRTIs), including viruses harboring multiple thymidine analog mutations (TAMS), including the M41L and L210W mutations, and the L74V and M184V mutations.
Many people did not achieve durable virologic benefits from these drugs, mainly because they had previously taken and developed resistance to the nucleoside analog reverse transcriptase inhibitors (NRTIs).
Currently, there are 4 groups of antiretroviral medications used to treat HIV/AIDS: 1) nucleoside/nucleotide reverse transcriptase inhibitors or "nukes," 2) non-nucleoside reverse transcriptase inhibitors or "non-nukes," 3) protease inhibitors, and 4) entry inhibitors (see table below).

Full browser ?